{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-011680","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2022-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.322241+00:00","generated_at":"2026-06-26T18:16:46.133494+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Eledon Pharma reports FY2021 net loss of $34.5M; cash $84.8M into 2024","bullets":["Net loss for Q4 2021 was $8.8M ($0.59/share); FY2021 net loss $34.5M ($2.33/share).","R&D expense rose to $23.7M in FY2021 from $6.1M in FY2020, driven by tegoprubart trials.","Cash and equivalents $84.8M at Dec 31, 2021, down from $114.2M a year earlier.","Topline Phase 2a tegoprubart data in ALS expected in Q2 2022; kidney, IgAN, islet data in Q4 2022.","No revenue recorded; net loss widened due to increased clinical development costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-011680","json":"https://secwatch.observer/filing/0001564590-22-011680.json","markdown":"https://secwatch.observer/filing/0001564590-22-011680.md","text":"https://secwatch.observer/filing/0001564590-22-011680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000156459022011680/0001564590-22-011680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000156459022011680/eldn-8k_20220324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T18:16:46.133494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}